title: Double trouble for CML.
abstract: Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.
authors.affiliation: John B. Little Center for Radiation Sciences, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA. Email: sarosiek@hsph.harvard.edu.
authors.forename: Kristopher
authors.initials: K
authors.lastname: Sarosiek
mesh_terms: D016044:Fusion Proteins, bcr-abl; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D009364:Neoplasm Recurrence, Local; D009536:Niacinamide / Q000031:analogs & derivatives; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; C000621806:asciminib; D009536:Niacinamide; D016044:Fusion Proteins, bcr-abl